Potential utility of combination therapy with nateglinide and telmisartan for metabolic derangements in zucker fatty rats

Hormone and Metabolic Research

Volumn 39, Issue 12, 2007, Pages 889-893

  Kajioka, T ^a   Miura, K ^a   Kitahara, Y ^a   Yamagishi, S ^b  

^a Pharmaceutical Research Laboratories   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Insulin resistance; Metabolic syndrome; Postprandial hyperglycemia; Telmisartan

Indexed keywords

ADIPONECTIN; FATTY ACID; INSULIN; NATEGLINIDE; TELMISARTAN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIET RESTRICTION; DRUG USE; FATTY ACID BLOOD LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MORNING DOSAGE; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ZUCKER DIABETIC FATTY RAT;

ADIPONECTIN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CYCLOHEXANES; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; METABOLIC DISEASES; PHENYLALANINE; RATS; RATS, ZUCKER;

RATTUS;

EID: 38149109978     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-992798     Document Type: Article

References (18)

1. Scheen AJ. Management of the metabolic syndrome. Minerva Endocrinol 2004; 29: 31-45
2. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003; 92: 10J-17J
3. Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002; 45: 461-475
4. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17: 189-212
5. Ceriello A. Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 1999; 12: 42-46
6. Ronson RS, Nakamura M, Vinten-Johansen J. The cardiovascular effects and implications of peroxynitrite. Cardiovasc Res 1999; 44: 47-59
7. Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharm Des 2002; 8: 155-166
8. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-2299
9. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004; 43: 993-1002
10. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057
11. Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypothese 2005; 64: 476-478
12. Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des 2004; 10: 2779-2786
13. Kitahara Y, Miura K, Takesue K, Mine T, Wada R, Uchida Y, Ito S, Yagihashi S. Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes. Metabolism 2002; 51: 1452-1457
14. Yamagishi S, Nakamura K, Jinnouchi Y, Takenaka K, Imaizumi T. Molecular mechanisms for vascular injury in the metabolic syndrome. Drugs Exp Clin Res 2005; 31: 123-129
15. Rosen P, Osmers A. Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose. Horm Metab Res 2006; 38: 575-580
16. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002
17. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 2006; 48: 51-57
18. Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28: 757-758